Article summary
The European Medicines Agency (EMA) has adopted a reflection paper on using AI and machine learning (ML) in drug development after considering extensive feedback during the consultation period with revision to key parts. The updated paper also includes changes based on the recent EU AI Act.
To continue reading this news article, as well as thousands of others like it, sign in with LexisNexis or register for a free trial